A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites

Publisher： Karger

E-ISSN： 1423-0232|82|6|315-320

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.6, 2012-05, pp. : 315-320

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Different Response to the Long-Acting Somatostatin Analogues Lanreotide and Octreotide in a Patient with a Malignant Carcinoid

By  

Oncology, Vol. 60, Iss. 2, 2001-02 ,pp. : 141-145

Karger

Access to resources Recommend Favorite

Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study

By  

CANCER, Vol. 120, Iss. 16, 2014-08 ,pp. : 2457-2463

John Wiley & Sons Inc

Access to resources Recommend Favorite

Palliation of Symptomatic Malignant Ascites: An (Often) Unmet Need

By  

Oncology, Vol. 82, Iss. 6, 2012-05 ,pp. : 313-314

Karger

Access to resources Recommend Favorite

Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting β2-agonists: addition of montelukast in an open-label pilot study

By Dupont Lieven   Potvin Emmanuel   Korn Dana   Lachman Albert   Dramaix Michèle   Gusman Julie   Peché Rudi  

Current Medical Research and Opinion, Vol. 21, Iss. 6, 2005-06 ,pp. : 863-870

Informa Healthcare

Access to resources Recommend Favorite

Octreotide long‐acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: A population‐based analysis

By  

CANCER, Vol. 120, Iss. 13, 2014-07 ,pp. : 2039-2049

John Wiley & Sons Inc

Access to resources Recommend Favorite